GenSciP-111

GenSciP-111 is a **preclinical siRNA therapeutic candidate** reported to be developed by **Changchun Genescience Pharmaceuticals** for **idiopathic pulmonary fibrosis**. Publicly accessible drug-database information identifies it as an inhibitor of **connective tissue growth factor**, also known as **cellular communication network factor 2**, implying an RNA-interference mechanism intended to reduce CTGF expression and thereby attenuate profibrotic signaling and extracellular matrix deposition in fibrotic lung disease. No public clinical-trial record, regulatory approval, or detailed sequence-level disclosure was identified in the sources reviewed, so the program appears to remain an early-stage, sparsely described asset.